HER2 Support Group Forums - View Single Post

SuzEQ · 11-06-2009, 09:26 AM

In response to Laurel's recent post and Rich's comments, wouldn't Zometa every 6 months be standard of care anyway, especially if you are receiving an AI? Not sure how they can prohibit this in the Neratinib study. I am on the SWOG307 study but if I had not gone on this, I would have been taking Zometa every 6 months anyway. The SWOG307 study is looking at higher doses of bisphosphonates in early stage disease to see if there is a survival benefit. There is an afternoon of bisphosphonate discussion planned for the San Antonio conference so I'm interested in any results that are presented. Neratinib may be a hot topic, too, so it should be an interesting conference. Will anyone be live blogging from the conference?

11-06-2009, 09:26 AM	#23
SuzEQ Member Join Date: Jun 2009 Posts: 7	Re: Neratinib Trial 09 In response to Laurel's recent post and Rich's comments, wouldn't Zometa every 6 months be standard of care anyway, especially if you are receiving an AI? Not sure how they can prohibit this in the Neratinib study. I am on the SWOG307 study but if I had not gone on this, I would have been taking Zometa every 6 months anyway. The SWOG307 study is looking at higher doses of bisphosphonates in early stage disease to see if there is a survival benefit. There is an afternoon of bisphosphonate discussion planned for the San Antonio conference so I'm interested in any results that are presented. Neratinib may be a hot topic, too, so it should be an interesting conference. Will anyone be live blogging from the conference?